Literature DB >> 23146787

Behavioral and intellectual functioning in patients with tyrosinemia type I.

Monika Pohorecka1, Marta Biernacka, Anna Jakubowska-Winecka, Marcin Biernacki, Katarzyna Kuśmierska, Agnieszka Kowalik, Jolanta Sykut-Cegielska.   

Abstract

INTRODUCTION: In tyrosinemia type I (TT1) increased level of tyrosine and phenylalanine (both precursors of neurotransmitters), may potentially influence patients' cognitive development. AIM OF THE STUDY: Was to evaluate if the children during the treatment with phenylalanine- and tyrosine-restricted diet and nitisinone present with cognitive, emotional or behavioral problems and to find out whether plasma tyrosine and phenylalanine levels may have impact on this.
MATERIAL AND METHODS: Cognitive development and behavior, together with plasma tyrosine and phenylalanine levels, were analyzed in eight patients during their first five years of nitisinone treatment. Psychological examination has been done using standard diagnostic methods: the Wechsler Intelligence Scale for Children (WISC-R) and Child Behavior Checklist CBCL/4-18 (parents version).
RESULTS: The results showed that in the patients with TT1, attention deficit is not rare, and may be connected with the variation of the plasma tyrosine level. Moreover the reverse correlation between attention deficit and results from verbal scale may suggest decreased ability to verbal reasoning, comprehension, verbal expression and school difficulties.
CONCLUSIONS: What is significant for the presence of attention disorders and the related difficulties in using the intellectual potential is not the level of tyrosine (high vs. low), but its changes (stability vs. instability). Therapeutic trials to stabilize the tyrosine level could alleviate the difficulties in focusing attention. Following a diet is necessary for keeping the normal level of tyrosine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146787

Source DB:  PubMed          Journal:  Pediatr Endocrinol Diabetes Metab        ISSN: 2083-8441


  12 in total

1.  Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice.

Authors:  Megan A Hillgartner; Sarah B Coker; Ashton E Koenig; Marissa E Moore; Elizabeth Barnby; Gordon G MacGregor
Journal:  J Inherit Metab Dis       Date:  2016-06-06       Impact factor: 4.982

Review 2.  Quality of life, psychological adjustment, and adaptive functioning of patients with intoxication-type inborn errors of metabolism - a systematic review.

Authors:  Nina A Zeltner; Martina Huemer; Matthias R Baumgartner; Markus A Landolt
Journal:  Orphanet J Rare Dis       Date:  2014-10-25       Impact factor: 4.123

3.  Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls.

Authors:  Willem G van Ginkel; Rianne Jahja; Stephan C J Huijbregts; Anne Daly; Anita MacDonald; Corinne De Laet; David Cassiman; François Eyskens; Irene M L W Körver-Keularts; Philippe J Goyens; Patrick J McKiernan; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2016-06-29       Impact factor: 4.123

4.  Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1.

Authors:  Willem G van Ginkel; Danique van Vliet; Johannes G M Burgerhof; Pim de Blaauw; M Estela Rubio Gozalbo; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  PLoS One       Date:  2017-09-26       Impact factor: 3.240

5.  Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet.

Authors:  María Ignacia García; Alicia de la Parra; Carolina Arias; Miguel Arredondo; Juan Francisco Cabello
Journal:  Mol Genet Metab Rep       Date:  2017-03-26

6.  Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.

Authors:  María Luz Couce; Paula Sánchez-Pintos; Luís Aldámiz-Echevarría; Isidro Vitoria; Victor Navas; Elena Martín-Hernández; Camila García-Volpe; Guillem Pintos; Luis Peña-Quintana; Tomás Hernández; David Gil; Félix Sánchez-Valverde; María Bueno; Iria Roca; Encarna López-Ruzafa; Carmen Díaz-Fernández
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

7.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

Review 8.  Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).

Authors:  Anibh Martin Das
Journal:  Appl Clin Genet       Date:  2017-07-24

Review 9.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

10.  The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.

Authors:  Willem G van Ginkel; Hannah E van Reemst; Nienke S Kienstra; Anne Daly; Iris L Rodenburg; Anita MacDonald; Johannes G M Burgerhof; Pim de Blaauw; Jennifer van de Krogt; Saikat Santra; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Nutrients       Date:  2019-11-18       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.